20090309
 Drug-Industry Shakeout Hits Small Firms Hard --- Another Wave of Acquisitions Is Likely as Companies Worry About Their Drug Pipelines and Health-Care Change   By Johnson, Avery; Winslow, Ron, The Wall Street Journal,  Mar 10, 2009  Factors including existing partnerships, the timing of patent expirations and how well drug makers can absorb multiple acquisitions could affect who will be a buyer and who will be a seller. Bristol-Myers sold its ConvaTec wound-care business last May for $4.1 billion and offered a $720 million partial initial public offering for its nutritional business last month -- divestitures that could either add to its war chest for deals or make it a more attractive takeover target.   
